Juvenile Arthritis News

EULAR released 18 evidence-based recommendations for the management of familial Mediterranean fever.

In a public meeting held in Washington, D.C. by the FDA, the American College of Rheumatology testified in support of reauthorization of the Biosimilar User Fee Act.

Momenta Pharmaceuticals and Mylan announced a collaboration to develop, manufacture and commercialize six of Momenta’s current biosimilar medications created by Momenta, including a biosimilar to abatacept for patients with rheumatoid arthritis, according to a press release.

According to results of a recently presented study, patients with rheumatoid arthritis who did not respond to treatment with a tumor necrosis factor inhibitor and received a second biologic therapy that targeted another pathway were more likely to have better outcomes than patients who received a second tumor necrosis factor inhibitor.

The American Autoimmune Related Diseases Association has released a report available to the public that addresses topics in autoimmune diseases, research and patient information following a one-day autoimmune summit in Washington, D.C., that involved about 20 researchers.

Baxalta Inc. and Momenta Pharmaceuticals Inc. recently announced the adalimumab biosimilar M923 manufactured by the companies has met its primary endpoint in a pharmacokinetic trial, demonstrating bioequivalence to AbbVie’s adalimumab sourced from the both United States and European Union, according to a company press release.

In a study of German patients with rheumatic diseases treated with biologics, the incidence of reactivation of the hepatitis B virus was uncommon, according to recently presented data.

A recently presented case-control study showed pediatric patients who experience infection with Clostridium difficile may develop reactive arthritis that is either unrecognized or misdiagnosed as septic arthritis.

Royal Philips announced the release of Lumify, a subscription-based smart device ultrasound solution for purchase by licensed U.S. health care providers and organizations.

Although the use of interventional and diagnostic musculoskeletal ultrasound has increased among many providers, according to researchers from the University of Florida, the value of added testing is unclear.